Business Description

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching, developing, and commercializing therapeutics for life-threatening diseases. The company is best known for its antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, and COVID-19. In recent years, Gilead has expanded its portfolio to include oncology and cell therapy treatments. The company operates globally, providing medicines to address unmet medical needs across various therapeutic areas.

Everything on Gilead Sciences, Inc.

Revenue (FY2025) $29.44B
YoY growth +2.4%
Operating margin 34.0%
Direction Expanding
Gross margin 78.8%
Net margin 28.9%

Earnings Transcripts

View all transcripts ↗

Leadership & board

View leadership ↗

Acquisitions

Share Repurchase Program

Total authorized
$5.0 billion (2020 Program, authorized Q1 2020) plus $6.0 billion (2025 Program, authorized Q3 2025, commencing upon completion of the 2020 Program); both have no fixed expiration
Remaining (as of December 31, 2025)
$6,802 million (approximate dollar value of shares that may yet be purchased under the programs as of December 31, 2025)
Latest FY repurchased
$1,922 million (FY2025 'Repurchases of common stock under repurchase programs' per the 10-K cash flow statement)

Customer Concentration

Historically, approximately 90% of Gilead's gross product sales in the U.S. have been to three large wholesalers - Cardinal Health, Cencora and McKesson - and their specialty distributor affiliates. In fiscal 2025, as a percentage of total gross product sales, Cardinal Health accounted for 29%, McKesson 24% and Cencora 21% (per the 10-K 'Revenues from Major Customers' disclosure).

Recent SEC Filings

2026-08-04 Reported quarterly results View filing ↗
2026-05-20 Entered a material agreement (+2 more) View filing ↗
2026-05-07 Reported quarterly results View filing ↗
2026-05-04 Shareholder vote results View filing ↗
2026-04-28 Regulation FD disclosure (+1 more) View filing ↗
2026-02-23 Entered a material agreement (+1 more) View filing ↗
2026-02-10 Reported quarterly results View filing ↗
2025-11-19 Leadership change (directors/officers) View filing ↗
2025-10-30 Reported quarterly results View filing ↗
2025-10-06 Regulation FD disclosure View filing ↗
2025-08-14 Leadership change (directors/officers) View filing ↗
2025-08-07 Reported quarterly results View filing ↗

More Companies

See how VectorShift works for your firm

Request Demo